Click here to close now.


News Feed Item

DiagnoCure Announces First Quarter 2014 Results

QUEBEC CITY, March 14, 2014 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation") today reported financial and operational results for the first quarter 2014 ended January 31, 2014. The Corporation announced a net loss of $529,739 or $0.01 per share for this quarter. At the end of the quarter, cash, cash equivalents and short-term investments stood at $3,543,029.

During the first quarter ended January 31, 2014, PCA3 royalties paid to DiagnoCure by Hologic decreased by 12% compared with the same quarter in 2013. Quarterly worldwide sales of less than $US2.0 million are not meeting the Corporation's expectations for a test whose value is supported by an ever-increasing number of clinical studies and publications. In 2013 alone, 54 new papers were published on PCA3. Nearly 250 papers reporting the clinical utility of PCA3 have now been published. Consequently, the underperformance of PCA3 sales cannot be explained by a declining interest from the medical community. DiagnoCure believes that: (1) more resources need to be committed to the PCA3 marketing and sales effort and (2) the product needs to be made available on an instrument platform more suitable to the prostate cancer diagnostic and screening market. For these reasons, DiagnoCure has continued to pursue active discussions to purchase Hologic's entire prostate-oncology business unit. The intent of the Corporation in regaining all rights to PCA3 is to capitalize on its internal expertise to develop and manufacture an in-house Polymerase Chain Reaction (PCR) version of the PCA3 test. Data already generated by DiagnoCure indicates that performance of the PCR-based PCA3 test is similar to that of the currently marketed PROGENSA® PCA3 assay.

"DiagnoCure's board of directors is pressing to resolve the current situation with Hologic to ensure that PCA3 gets the attention we believe it deserves. Meanwhile the study on our new multi-marker prostate cancer test is proceeding on schedule and discussions regarding commercialization of Previstage™ GCC are progressing," stated Dr. Yves Fradet, Chairman of the Board.

Results of the First Quarter 2014

Total revenues for the first quarter of 2014 were $146,969 compared with $167,916 for the same period of 2013. This decrease of $20,947 or 12% is attributable to Hologic Gen-Probe PCA3 royalties. In the first quarter of 2014, royalty revenues from Hologic Gen-Probe were $146,969, compared to $167,916 for the same period of 2013. This decrease is attributable to a decrease of 28% in U.S. royalty revenues and 4% in European royalty revenues as compared to the same period in 2013.

Operating expenses decreased by $279,445, to $676,708 for the first three months of 2014 from $956,153 for the same period of 2013. This decrease is mainly attributable to reduction in professional fees and amortization of the intangible asset. Total operating expenses decreased primarily as a result of the following:

  • Research and development expenses, net of investment tax credits, decreased by $165,056, to $239,803 for the first three-month of 2014 from $404,859 for the same period of 2013. This decrease in research and development expenses is attributable to the amortization charge of the GCC intangible asset following the review of its useful life and to the amortization of the Shc intangible asset, since the Corporation recognized a full impairment charge in the last quarter of fiscal 2013.
  • General and administrative expenses decreased by $106,322, to $403,001 for the first three-month period of 2014 from $509,323 for the same period of 2013. This decrease is attributable to reduction in professional fees and stock-based compensation expenses.

Financial Data
  For the three months periods ended
January 31
2014 2013
  $ $
License and royalty revenues 146,969 167,916
Total revenues 146,969 167,916
Operating expenses (before stock-based compensation, depreciation and amortization) 574,242 698,116
Net loss (before stock-based compensation, depreciation and amortization) (427,273) (530,200)
Stock-based compensation 17,613 38,682
Depreciation of property, plant and equipment 14,931 19,834
Amortization of intangible asset 69,922 199,521
Net loss and comprehensive loss (529,739) (788,237)
Basic and diluted net loss per share (0.01) (0.02)
Weighted average number of common shares outstanding 43,040,471 43,040,471
Consolidated Balance Sheets    
  January 31, 2014 October 31, 2013
Cash, cash equivalents and short term investments 3,543,029 4,190,296
Total assets 7,193,241 7,849,267
Shareholders' equity 6,497,135 7,009,261
Number of commons shares outstanding 43,040,471 43,040,471

Annual and Special Meeting of Shareholders

DiagnoCure confirms that the Annual and Special Meeting of its shareholders will be held as follows:

TIME:    Thursday, April 17, 2014      LOCATION:    McCarthy Tétrault's offices
    3:00 p.m. (EDT)             1000 de la Gauchetière Street West
            Suite 2500
            Montréal (Québec) H3B 0A2

About DiagnoCure

DiagnoCure (TSX: CUR) (OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, please visit

Forward‐looking statements

This release may contain forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates", "assumes", "believes", "estimates", "expects", "intend", "may", "plans", "projects", "should", "will", or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forward‐looking statements. For instance, any forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues, including those related to PROGENSA® PCA3, are based on management expectations and such outcome may vary materially depending on global political and economic conditions, dependence on collaboration partners, uncertainty of healthcare reimbursement, and marketing and distribution challenges. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.

SOURCE DiagnoCure inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
In recent years, at least 40% of companies using cloud applications have experienced data loss. One of the best prevention against cloud data loss is backing up your cloud data. In his General Session at 17th Cloud Expo, Sam McIntyre, Partner Enablement Specialist at eFolder, presented how organizations can use eFolder Cloudfinder to automate backups of cloud application data. He also demonstrated how easy it is to search and restore cloud application data using Cloudfinder.
The Internet of Everything is re-shaping technology trends–moving away from “request/response” architecture to an “always-on” Streaming Web where data is in constant motion and secure, reliable communication is an absolute necessity. As more and more THINGS go online, the challenges that developers will need to address will only increase exponentially. In his session at @ThingsExpo, Todd Greene, Founder & CEO of PubNub, exploreed the current state of IoT connectivity and review key trends and t...
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessi...
As organizations shift towards IT-as-a-service models, the need for managing & protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection & E-Discovery of your data - whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise.
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs, and improve customer experience – effectively the same challenges they have always had in growing their business. The exciting thing about the IoT industry is now these decisions can be better, faster, and smarter. Now ...
Continuous processes around the development and deployment of applications are both impacted by -- and a benefit to -- the Internet of Things trend. To help better understand the relationship between DevOps and a plethora of new end-devices and data please welcome Gary Gruver, consultant, author and a former IT executive who has led many large-scale IT transformation projects, and John Jeremiah, Technology Evangelist at Hewlett Packard Enterprise (HPE), on Twitter at @j_jeremiah. The discussion...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Discussions of cloud computing have evolved in recent years from a focus on specific types of cloud, to a world of hybrid cloud, and to a world dominated by the APIs that make today's multi-cloud environments and hybrid clouds possible. In this Power Panel at 17th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the importance of customers being able to use the specific technologies they need, through environments and ecosystems that expose their APIs to make true ...
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound...
Microservices are a very exciting architectural approach that many organizations are looking to as a way to accelerate innovation. Microservices promise to allow teams to move away from monolithic "ball of mud" systems, but the reality is that, in the vast majority of organizations, different projects and technologies will continue to be developed at different speeds. How to handle the dependencies between these disparate systems with different iteration cycles? Consider the "canoncial problem"...
The cloud. Like a comic book superhero, there seems to be no problem it can’t fix or cost it can’t slash. Yet making the transition is not always easy and production environments are still largely on premise. Taking some practical and sensible steps to reduce risk can also help provide a basis for a successful cloud transition. A plethora of surveys from the likes of IDG and Gartner show that more than 70 percent of enterprises have deployed at least one or more cloud application or workload. Y...